Growth in prevalence of primary progressive multiple sclerosis is significantly impacting market development

WILMINGTON, DELAWARE, UNITED STATES, October 25, 2023 /EINPresswire.com/ -- Primary Progressive Multiple Sclerosis Treatment Market is expected to witness significant growth in the coming years, according to a new report. The market was valued at USD 828.4 million in 2021 and is projected to reach over USD 3.2 billion by 2031, expanding at a compound annual growth rate of 14.7% during the forecast period.

𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗮 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗦𝗮𝗺𝗽𝗹𝗲 𝗼𝗳 𝘁𝗵𝗶𝘀 𝗣𝗿𝗲𝗺𝗶𝘂𝗺 𝗥𝗲𝗽𝗼𝗿𝘁 @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85270

𝗚𝗿𝗼𝘄𝗶𝗻𝗴 𝗚𝗲𝗿𝗶𝗮𝘁𝗿𝗶𝗰 𝗣𝗼𝗽𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗗𝗿𝗶𝘃𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 𝗚𝗿𝗼𝘄𝘁𝗵:

 The rising geriatric population globally is a major factor fueling the demand for primary progressive multiple sclerosis treatment. As age is a high-risk factor, the increasing elderly demographic will support market expansion over the forecast period.

𝗜𝗻𝗰𝗿𝗲𝗮𝘀𝗲 𝗶𝗻 𝗚𝗲𝗿𝗶𝗮𝘁𝗿𝗶𝗰 𝗣𝗼𝗽𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗗𝗿𝗶𝘃𝗶𝗻𝗴 𝗗𝗲𝗺𝗮𝗻𝗱

Rise in prevalence of PPMS across the globe due to the growing geriatric population is a key factor fueling demand. Women are more susceptible to multiple sclerosis than men. With more people being diagnosed with the disease, treatment needs are increasing. Effectiveness of available drugs and ongoing research for new therapies are further supporting market growth.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗗𝗿𝗶𝘃𝗲𝗿𝘀:

Growing prevalence of multiple sclerosis worldwide

Increasing research and development activities for novel treatment options

Rising healthcare expenditure in many countries

𝗠𝗮𝗿𝗸𝗲𝘁 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀:

High cost of treatment and lack of reimbursement in some regions

Absence of approved disease-modifying therapies for primary progressive MS

Long development timelines and high failure rates of drug candidates

𝗠𝗮𝗿𝗸𝗲𝘁 𝗧𝗿𝗲𝗻𝗱𝘀:

Shift from generic drugs to specialty medicines

Focus on development of oral and more efficacious drugs

Emergence of biologics and monoclonal antibodies

𝐈𝐧𝐪𝐮𝐢𝐫𝐞 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐛𝐞𝐟𝐨𝐫𝐞 𝐩𝐮𝐫𝐜𝐡𝐚𝐬𝐞: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=85270

𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻

𝗕𝘆 𝗗𝗿𝘂𝗴 𝗧𝘆𝗽𝗲

Approved Drugs

Pipeline Drugs

𝗕𝘆 𝗗𝗶𝘀𝘁𝗿𝗶𝗯𝘂𝘁𝗶𝗼𝗻 𝗖𝗵𝗮𝗻𝗻𝗲𝗹

Retail Pharmacies

E-commerce

Others

𝗣𝗿𝗼𝗺𝗶𝗻𝗲𝗻𝘁 𝗽𝗹𝗮𝘆𝗲𝗿𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗴𝗹𝗼𝗯𝗮𝗹 𝗺𝗮𝗿𝗸𝗲𝘁

Hoffmann-La Roche Ltd.

Sanofi

Mapi Pharma Ltd.

Atara Biotherapeutics

Takeda Pharmaceuticals International, Inc.

AB Science

Mallinckrodt

𝗛𝗮𝘃𝗲 𝗔𝗻𝘆 𝗤𝘂𝗲𝗿𝘆? 𝗔𝘀𝗸 𝗢𝘂𝗿 𝗘𝘅𝗽𝗲𝗿𝘁𝘀 https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep_id=85270

𝗦𝗼𝗺𝗲 𝗤𝘂𝗲𝘀𝘁𝗶𝗼𝗻𝘀 𝗔𝗻𝘀𝘄𝗲𝗿𝗲𝗱 𝗶𝗻 𝘁𝗵𝗶𝘀 𝗥𝗲𝗽𝗼𝗿𝘁:

How big was the global primary progressive multiple sclerosis treatment market in 2021?

How much worth would the industry be in 2031?

What will be the CAGR during the forecast period?

What was the CAGR during the period of 2017 to 2021?

Which region is expected to hold major share during the forecast period?

Who are the prominent players in the global primary progressive multiple sclerosis treatment market?

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡-

Benign Prostatic Hyperplasia Treatment Market

Increasing adoption of minimally invasive surgeries is fueling benign prostatic hyperplasia treatment market expansion. Rising male elderly population is expected to drive market growth.

Psoriatic Arthritis Therapeutics Market

Technological advancements in drug delivery system, is another factor that is anticipated to stimulate the psoriatic arthritis therapeutics market share in the coming years. Increasing research & development activities is a major factor that is anticipated to escalate the market growth

Nikhil Sawlani
Transparency Market Research Inc.
+ +1 518-618-1030
email us here
Visit us on social media:
Twitter
LinkedIn
YouTube

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.